Drug interaction profile for GSK2248761, a next generation non‐nucleoside reverse transcriptase inhibitor

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In healthy subjects, GSK2248761 was shown to be safe and well tolerated with single doses up to 1200 mg once daily and with multiple doses up to 800 mg once daily for 7 days. Furthermore, a phase IIa monotherapy study demonstrated that GSK2248761 30 to 800 ...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of clinical pharmacology 2012-08, Vol.74 (2), p.336-345
Hauptverfasser:	Piscitelli, Steve, Kim, Joseph, Gould, Elizabeth, Lou, Yu, White, Scott, de Serres, Mark, Johnson, Mark, Zhou, Xiao‐Jian, Pietropaolo, Keith, Mayers, Douglas
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenine - administration & dosage Adenine - analogs & derivatives Adenine - pharmacokinetics Androstenes - administration & dosage Androstenes - pharmacokinetics Anti-HIV Agents - administration & dosage Anti-HIV Agents - pharmacokinetics antiretroviral therapy Antiviral activity Antiviral agents Atazanavir Sulfate Atorvastatin Biological and medical sciences Blood Contraceptives, Oral - administration & dosage Contraceptives, Oral - pharmacokinetics Cross-Over Studies CYP2D6 protein Cytochrome P-450 CYP2D6 - metabolism Cytochrome P-450 CYP2D6 Inhibitors Cytochrome P-450 CYP3A - metabolism Cytochrome P-450 CYP3A Inhibitors Cytochrome P450 Darunavir Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Deoxycytidine - pharmacokinetics Double-Blind Method Drug Combinations Drug interaction Drug Interactions drug‐drug interaction EKG Emtricitabine Ethinyl Estradiol - administration & dosage Ethinyl Estradiol - pharmacokinetics ethinylestradiol Female Fluorobenzenes - administration & dosage Fluorobenzenes - pharmacokinetics Heptanoic Acids - administration & dosage Heptanoic Acids - pharmacokinetics HIV‐1 infection Human immunodeficiency virus 1 Human viral diseases Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Indoles - administration & dosage Indoles - pharmacokinetics Infection Infectious diseases Least-Squares Analysis Linear Models Lopinavir Lopinavir - administration & dosage Lopinavir - pharmacokinetics Male Medical sciences NNRTI non-nucleoside reverse transcriptase inhibitors Oligopeptides - administration & dosage Oligopeptides - pharmacokinetics Organophosphonates - administration & dosage Organophosphonates - pharmacokinetics Patient Safety Pharmacology. Drug treatments Phosphinic Acids - administration & dosage Phosphinic Acids - pharmacokinetics Probes Pyridines - administration & dosage Pyridines - pharmacokinetics Pyrimidines - administration & dosage Pyrimidines - pharmacokinetics Pyrroles - administration & dosage Pyrroles - pharmacokinetics Pyrrolidinones - administration & dosage Pyrrolidinones - pharmacokinetics Raltegravir Potassium Reverse Transcriptase Inhibitors - administration & dosage Reverse Transcriptase Inhibitors - pharmacokinetics Risk Assessment Ritonavir Ritonavir - administration & dosage Ritonavir - pharmacokinetics Rosuvastatin Calcium Simvastatin Simvastatin - administration & dosage Simvastatin - pharmacokinetics Sulfonamides - administration & dosage Sulfonamides - pharmacokinetics Tenofovir Urinalysis Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!